Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trial

• Allogene Therapeutics announced preliminary results from its Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases.
• Most patients assessed for skin-predominant systemic sclerosis showed sustained skin improvement, including those treated without lymphodepleting chemotherapy.
• Early safety findings showed no dose-limiting toxicities; most patients assessed for skin improvement remained off background immunosuppressive therapy.
• The results will be presented today, November 9, 2026, at the American College of Rheumatology Convergence.
• Dose escalation continues to guide selection of a Phase 2 regimen, with the next data readout planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090800PRIMZONEFULLFEED9872660) on November 09, 2026, and is solely responsible for the information contained therein.